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Juvenile idiopathic arthritis (JIA) comprises a poorly understood group of chronic, childhood onset,
autoimmune diseases with variable clinical outcomes. We investigated whether proﬁling of the synovial
ﬂuid (SF) proteome by a ﬂuorescent dye based, two-dimensional gel (DIGE) approach could distinguish
patients in whom inﬂammation extends to affect a large number of joints, early in the disease process.
SF samples from 22 JIA patients were analyzed: 10 with oligoarticular arthritis, 5 extended oligoarticular
and 7 polyarticular disease. SF samples were labeled with Cy dyes and separated by two-dimensional
electrophoresis. Multivariate analyses were used to isolate a panel of proteins which distinguish patient
subgroups. Proteins were identiﬁed using MALDI-TOF mass spectrometry with expression further
veriﬁed by Western immunoblotting and immunohistochemistry. Hierarchical clustering based on the
expression levels of a set of 40 proteins segregated the extended oligoarticular from the oligoarticular
patients (p < 0.05). Expression patterns of the isolated protein panel have also been observed over
time, as disease spreads to multiple joints. The data indicates that synovial ﬂuid proteome proﬁles
could be used to stratify patients based on risk of disease extension. These protein proﬁles may also
assist in monitoring therapeutic responses over time and help predict joint damage.
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Introduction
Around one in every thousand children in the U.K. suffer
from juvenile idiopathic arthritis (JIA).1 The worldwide reported
incidence varies on a geographical basis, from 0.7 per 1000 in
USA to 4.0 per 1000 in Australia.2 JIA is a heterogeneous group
of inﬂammatory disorders primarily affecting the musculosk-
eletal system. Of the seven subsets of JIA identiﬁed according
to the ILAR classiﬁcation,3 three, oligoarticular, extended
oligoarticular, and polyarticular are the commonest. Adverse
outcomes can present to varying degrees regardless of disease
subtype, but persistently inﬂamed joints are a major risk factor.4
Typically, the course of JIA is one of exacerbation and remis-
sion. In addition, nearly half the patients on disease modifying
therapies will have relapses after premature discontinuation
of treatment. The rate of relapses may be inﬂuenced by residual
synovial inﬂammation, not clinically apparent.5
Current clinical, laboratory or radiological parameters cannot
accurately predict disease extension. In approximately 25% of
children with oligoarticular JIA, over time the disease will
spread to involve many joints, extended oligoarticular disease.6
Extended oligo JIA is much more difﬁcult to treat due to its
characteristic resistance to ﬁrst-line therapies.7 Predictive tests
that forecast disease extension could allow subsequent treat-
ment decisions to be made in a preventative instead of a
reactive manner. It is pertinent to deﬁne more sensitive
markers for determining the risk of unremitting inﬂammatory
arthritis in JIA.
In this study, the synovial ﬂuid (SF) proteome of the
persistent oligoarticular patient subgroup is compared to that
of patients who show a spread after the ﬁrst 6 months to involve
ﬁve or more joints, the extended oligoarticular subgroup. If it
was possible to identify these children earlier, one could
instigate more effective therapies to prevent joint and periar-
ticular damage. Comparisons are also made between the SF
proteome of polyarticular patients who are diagnosed with
more than 4 joints involved within 6 months of onset. Com-
parison between the poly and extended oligoarticular group
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may help us understand why the latter are more resistant to
standard therapies than the former. Further differentiation of
the oligoarticular group will highlight those proteins which may
ultimately contribute to disease extension.
A pilot study uncovered fragments of extracellular matrix and
T-cell receptor proteins, products of the degradative proteolytic
environs of the recurrently inﬂamed knee.8 The synovial ﬂuid
proteome has a dynamic range of protein concentration
reﬂecting its ﬁltration from plasma, but speciﬁc additions are
made at the site of joint disease.9 The current investigation has
been designed to reveal SF protein expression patterns to
identify reliable predictors of JIA subgroup and track disease
course in detail. With further validation, these putative prog-
nostic biomarkers could improve the clinical management of
patients.
Methods
Patients. Twenty-two patients with newly diagnosed un-
treated JIA according to ILAR criteria entered this study and
were followed for 1 year. At the time of initial sampling, there
were 15 children with oligoarticular arthritis and 7 with RF-ve
polyarticular arthritis. At 1 year, 5 oligoarticular had been
reclassiﬁed as having extended oligoarticular JIA.
All patients were examined by a consultant rheumatologist
(M.E.R.) who conﬁrmed their diagnosis. For the purposes of
this study, only initial synovial ﬂuids from children with disease
duration of less than 6 months, and untreated disease, were
studied. Arthrocentesis and joint steroid injection was per-
formed according to clinical need. Clinical details recorded
included subtype of JIA, age, sex, disease duration, local and
erythrocyte sedimentation rate (ESR) and C-reactive protein
(CRP). Treatments applied after samples were removed are also
listed. Local inﬂammation was deﬁned as both joint swelling
and pain on physical examination.
All SFs were aspirated using an aseptic technique and plasma
obtained at the same procedure. Samples were immediately
centrifuged at 5000g for 15 min at 4 °C, aliquoted and stored
at-80 °C until for at least 1 year to allow for subsequent clinical
reclassiﬁcation. Medical Ethics Committee approval was ob-
tained for this study at Green Park Healthcare Trust and patient
assent and parent informed consent given (ORECNI 408/03).
Sample Preparation. Samples were dialyzed overnight at 4
°C in distilled water to remove salts, with 3.5 kDa cutoff Slide-
A-Lyzer cassettes (Pierce Biotechnology, Inc., Rockford, IL).
Each sample was snap frozen in liquid nitrogen and lyophilized
overnight on a freeze-dryer (Martin Christ GmbH, Osterode am
Harz, Germany). Samples were rehydrated in sample rehydra-
tion buffer (8 M Urea, 2% CHAPS and 0.002% bromophenol
blue; Invitrogen Ltd., Paisley, U.K.). Protein concentrations were
measured using the PlusOne 2-D Quant kit according to
manufacturer’s guidelines (GE Healthcare, Bucks, U.K.).
Difference In-Gel Electrophoresis (DIGE). DIGE was per-
formed at room temperature with Ettan IEF and vertical gel
systems and associated power supply, strips, gels and reagents
according to the manufacturer’s guidelines (GE Healthcare,
Bucks, U.K.). Each synovial ﬂuid and plasma sample was
minimally labeled with Cy5 and Cy3 ﬂuorescent dyes and
inclusion of an internal pooled standard (Cy2) according to the
manufacturer’s recommendations. A total of 50 μg of Cy5 and
Cy3 samples and Cy2 standard was combined and resuspended
in an equal volume of 2× sample buffer (8 M Urea, 130 mM
DTT, 4% (w/v) CHAPS, 2% (v/v) Pharmalyte 4-7). A 24 cm
Immobiline DryStrip pH 4-7 linear immobilized pH gradient
(IPG) strip was rehydrated overnight with the sample mix. The
ﬁrst-dimension separation of proteins by isoelectric focusing
(IEF) was performed for a total of 75 000 Vh (2 mA/5W limit
per strip) including a ﬁnal 8000 V step for 1 h to obtain high
quality resolution.
After IEF, the strips were equilibrated ﬁrst in 1% (w/v)
dithiothreitol and then 2.5% (w/v) iodoacetamide. IPG strips
were laid into single well 12% PAGE gels and sealed in with
1% agarose (w/v) in running buffer (25 mM Tris, 192 mM
Glycine, 0.1% (w/v) SDS and bromophenol blue). The second-
dimension separation was run at 0.75 W/gel for 19 h. Two
preparative pick gels loaded with 500 μg of unlabeled sample
were silver-stained for spot picking.
Image and Cluster Analysis. Prelabeled proteins were
visualized using a Typhoon 9410 imager (GE Healthcare, Bucks,
U.K.). Gel image analysis was performed with Progenesis
Samespots software version 2.0 build 2644.18003 (Nonlinear
Dynamics Ltd. Newcastle upon Tyne, U.K.), comprising gel
warping, DIGE normalization and comparison modules. Brieﬂy,
all gel images were aligned to a reference gel and the same
spot outlines overlaid onto all images ensuring no data was
omitted. The normalized volume (NV) for each spot on each
gel was calculated by the software from the Cy3 (or Cy5) to Cy
2 spot volume ratio. The software performs log transformation
of the spot volumes to generate normally distributed data. Log
normalized volume (LNV) was used in quantifying differential
expression.
Replicate normalized volumes were used to create ‘master’
gels for a series of corresponding SF or plasmas. Quantitative
differential spot analysis was performed on ‘master’ gels of the
patient subgroups. Pairwise comparisons were made to estab-
lish patient-to-patient and Cy3-to-Cy5 dye variations. Within
the Samespots review module, each comparison was ﬁltered
to ﬁnd the spots (a) with a p-value e0.05 for the paired t test,
and (b) having a greater than 2-fold change in average LNV
expression between the groups.
Expression data was analyzed using Epclust, a generic data
clustering, visualization, and analysis tool (http://www.bioinf.
ebc.ee/EP/EP/EPCLUST/). Hierarchical analysis reordered pro-
tein expression patterns in an agglomerative fashion, using the
unweighted pair-group average (UPGMA) clustering procedure.
Pearson ranked correlation was the similarity measure used
to group or separate the expression data. A heat map was
produced accompanied by a dendrogram depicting the extent
of similarity between the different groups in the samples.
Mass Spectrometry Identiﬁcation and Veriﬁcation. Protein
spots were excised from silver-stained 2D gels and digested by
use of the protocol described.10 Brieﬂy, the gel spots were
washed, reduced and alkylated followed by dehydration with
acetonitrile. The proteins were digested overnight with trypsin
(Promega, modiﬁed trypsin) at 37 °C, and the resulting peptides
were concentrated on a ZipTip micro puriﬁcation column and
eluted onto an anchor chip target for analysis on a Bruker
Autoﬂex III MALDI TOF/TOF instrument at Alphalyse A/S
(Odense, Denmark). The peptide mixture was analyzed in
positive reﬂector mode for accurate peptide mass determina-
tion and some of the peptides from each digest were analyzed
by MS/MS fragmentation for partial peptide sequencing.
Mass spectra were acquired in the 500-3000 m/z scan range.
The mass accuracy was calibrated to within 50 ppm using
calibration standards (BSA and transferrin) before each run.
The peptide masses obtained were used to query the nonre-
dundant sequence database (NRDB-NCBI 2008.04.15) for pro-
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tein identiﬁcation using the Mascot database search program
version 2.2.03. The NRDB2 database contains 6 373 249 entries
and is maintained and updated by the European Molecular
Biology Laboratory. Database search parameters considered:
(i) that the trypsin enzyme cleaves on the C-terminal side of
KR unless next residue is P, (ii) no ﬁxed modiﬁcations, (iii)
caramidomethyl (C) and oxidation (M) variable modiﬁcations,
(iv) up to 1 missed cleavage permitted with no ﬁxed modiﬁca-
tions, (v) peptide tolerance set at 60 ppm for the precursor ions,
and (vi) 0.7 Da mass tolerance for the fragment ions. The
acceptance criteria for PMF based identiﬁcations was a mini-
mum Mascot score of 50, using a 95% conﬁdence interval
threshold (p < 0.05). The peptide ions identiﬁed in this study
by MALDI-TOF and further CID MS/MS analysis independently
matched to single protein entries in the database.
Western Immunoblotting and Immunohistochemistry. West-
ern immunoblot was used to conﬁrm the mass spectrometry
ﬁndings of selected proteins and validate DIGE expression
levels across subgroups. The proteins within 10 μL denatured
synovial ﬂuid samples were separated using NuPAGE 4-12%
Bis-Tris gels and transferred to 0.45 μm PVDF membrane
(Millipore Corproration, MA) with an XCell II mini gel tank and
blot module, associated buffers and power supply, according
to the manufacturer’s guidelines (Invitrogen Ltd., Paisley, U.K.).
Nonspeciﬁc binding was blocked overnight at 4 °C using 5%
nonfat milk in PBS with 0.1% Tween 20 (PBST) (Sigma-Aldrich
Company Ltd., Gillingham, U.K.). Antihuman primary antibod-
ies to Complement C3c (Rabbit polyclonal ab15980; Abcam
PLC, Cambridge, U.K.), Vitamin D Binding Protein and Apo-
lipoprotein II (Monoclonal clones 359501 and 395906, respec-
tively; R&D Systems, Minneapolis, MN) were incubated with
blotted membranes at a dilution of 1:200 in PBST, for 1 h at
room temperature. After the membranes were washed 3 times
(5 min each) with PBST, they were incubated in horseradish
Figure 1. Fluorescence difference in-gel electrophoresis (DIGE) of synovial ﬂuid. DIGE reveals ∼1300 spots per gel within the pH 4-7
range for synovial ﬂuid (A). Spot ﬁltering on ‘master’ gels reveals 426 protein spots which are consistently expressed in synovial ﬂuid
across patient subgroups. A series of 40 synovial ﬂuid proteins, encircled and numbered above, were expressed at a 2-fold or higher
level than could be detected in the other two patient subgroups with statistical signiﬁcance by ANOVA (p < 0.05). Representative
protein expression patterns in synovial ﬂuid are shown in selected areas of ‘master’ gels (B) (37, 41, 892, 5, 566, 907, 542, 865, 947).
The colors (red, green, blue) used to encircle spots and spot numbers correlate to the clusters observed in the data after hierarchical
cluster analysis, shown in Figure 2B. Forty proteins spots were cut from replicate preparative gels and MALDI-TOF and nESI-MS/MS
were used to ascertain their identity.
Table 1. Patient Demographicsa
patient subgroup
patient subgroup oligo extended oligo poly total
Number 10 5 7 22
Age (years) 7.8 ( 4.15 6.0 ( 3.69 5.1 ( 2.31 6.6 ( 3.60
Male/Female (n) 5/5 0/5 1/6 6/16
Duration of JIA (weeks) 7.0 ( 6.50 11.8 ( 7.6 8.7 ( 6.06 8.7 ( 6.57
No. of Swollen Joints (n) 1.7 ( 0.82 4.0 ( 0.71 4.0 ( 1.63 3.0 ( 1.59
Serum CRP (mg/L) 7.5 ( 1.60 7.1 ( 2.11 13.6 ( 13.14 9.4 ( 7.75
ESR (mm/h) 10.7 ( 7.15 9.8 ( 4.02 50.3 ( 31.63 23.1 ( 25.93
NSAID (yes/no) 8/2 4/1 6/1 18/4
DMARD (yes/no) 0/10 2/3 0/7 2/20
Biologic (yes/no) 0/10 0/5 1/6 1/21
a Clinical and demographic characteristics of the study subjects. Values are the mean ( standard deviation or the number of subjects. CRP ) C-reactive
protein; ESR ) erythrocyte sedimentation rate. All study patients were rheumatoid factor negative.
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peroxidase conjugated secondary antibodies diluted to 1:2500-1:
5000 in PBST (Sigma-Aldrich Company Ltd., Gillingham, U.K.),
for 1 h at room temperature. After a further 6 washes, bands
were visualized using Supersignal West Pico chemiluminescent
substrate (Pierce Biotechnology, Inc., Rockford, IL), imaged
with a Autochemi CCD camera and analyzed with Labworks
software version 4.0.0.8 (UVP Ltd., Cambridge, U.K.).
Immunohistochemistry was performed on synovial mem-
brane biopsies to ascertain the localization and level of tissue
expression for selected proteins as well as providing further
validation. Synovial membrane tissues were obtained from each
patient by needle biopsy, coated in OCT compound, snap
frozen in liquid nitrogen and stored at-80 °C. Cryostat sections
of 7 μm were cut (Leica CM 1900; Meyer Instruments, Inc.),
ﬁxed in acetone at 4 °C for 10 min, air-dried and then
rehydrated in PBS for 10 min at room temperature. Endogenous
peroxidase was blocked by incubation with a 3% hydrogen
peroxide solution for 10 min. Sections were rinsed in PBS and
probed overnight at 4 °C with primary antibodies, as above,
diluted from 1/25 to 1/50 in PBS. Sections were incubated with
the Envision+ Dual link system sHRP (DAKO, Denmark)
according to the manufacturers guidelines for 30 min at RT.
Again sections were washed twice in PBS for ﬁve minutes,
stained with DAB solution, rinsed in water for 5 min and
counterstained in Mayers hematoxylin for 30 s. Sections were
washed then dehydrated through graded alcohols and xylene,
and allowed to air-dry for 5 min. Coverslips were mounted with
DPX medium (HD Supplies, Ayelsbury, UK) and sections
imaged with an Olympus BX41 light microscope and JVC 3CCD
camera (Olympus Ltd., Essex, UK).
Results
Proteome Description and Signiﬁcant Expression Pat-
terns. The simultaneous analysis of individual synovial ﬂuids
from 22 JIA patients (Table 1) was used to initially isolate joint-
speciﬁc protein expression proﬁles. A characteristic pattern of
high-abundance proteins form a series of typical charge trains
(see Figure 1A), consistent with previous work by other
laboratories and our own.8,11
Approximately 1300 spots per synovial ﬂuid gel image were
detected and matched across patients. Spot ﬁltering on ‘master’
Figure 2. Multivariate analysis of proteins differentially expressed across patient subgroups. Principle component analysis of proteins
differentially expressed across patient subgroups (A). Synovial ﬂuid proteome data from each patient is represented by single dots;
oligoarticular patients in pink, extended oligoarticular in blue and polyarticular in purple. The variance in the 40 selected proteins is
also represented by the numbers which are color coded with respect to the subsequent cluster analysis. Hierarchical cluster analysis
of proteins expressed with statistically signiﬁcant differences between patient subgroups (B). The interindividual and intergroup variation
in 40 preselected proteins is represented in heat map form. The protein expression data was reordered by hierarchical cluster analysis
(HCA) using Pearson centered correlation (UPGMA), revealing distinguishing expression patterns. Three main clusters of the proteins
are highlighted by the colored bars (red, green blue). Each patient sample is represented by a single numbered column (oligoarticular
O1-O9, extended oligoarticular EO1-EO5 and polyarticular P1-P7). The location of these spots from the comparative heat map is
shown in Figure 1A.
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gels reveals 426 protein spots which are consistently expressed
in synovial ﬂuid across patient subgroups. Attention was
focused on a series of 40 synovial ﬂuid proteins (circled and
labeled in Figure 1A) as these spots were expressed at a 2-fold
or higher level than could be detected in the other two patient
subgroups (p < 0.05). Certain proteins predominate in two
patient subgroups, for example, proteins 37 and 892 abundant
in both the polyarticular and extended oligoarticular patient
subgroups, whereas others apparently predominate in a single
subgroup, for example, proteins 5 and 907 in polyarticular or
protein 865 in oligoarticular patients (highlighted in Figure 1B).
Multivariate analysis was used to visualize inter-subgroup
expression patterns of the 40 selected protein spots.
Cluster and Statistical Analysis Differentiates Proteins
Which Segregate Patient Subgroups. Principle component
analysis of all data indicated that the synovial ﬂuid proteome
forms distinct groups of patients in an unsupervised fashion
(Figure 2A). Overlaps between subgroups are apparent, but the
variance is reduced in the panel of the 40 selected proteins.
These proteome patterns were further explored by hierarchical
cluster analysis and visualization in heat map form (Figure 2B).
Pearson ranked correlation revealed three distinctive clusters.
Cluster 1 contains proteins consistently overexpressed in both
extended oligoarticular and polyarticular patients, whereas
proteins in cluster 2 predominate only in the polyarticular
subgroup. Intriguingly, proteins in cluster 3 are consistently
overexpressed in the oligoarticular and polyarticular subgroups
relative to those patients with disease extension. It seemed
conceivable that these three distinct clusters could be used in
combination to differentiate disease subgroups. Further sta-
tistical analysis was used to test the signiﬁcance of inter-
subgroup patterns of the identiﬁed proteome clusters.
The Tukey-Kramer test reveals that patients with extended
oligoarticular and polyarticular disease have signiﬁcant differ-
ences in protein clusters 1 and 3 (p ) 0.001 for both) and
clusters 1 and 2 (p ) 0.001, p ) 0.009, respectively), when
compared to the oligoarticular subgroup. The unpaired t test
revealed proteins with signiﬁcant ﬂuctuations between patient
subgroups. The p-values are summarized in Table 2 and
overlaps between subgroup comparisons are represented by
Venn diagram in Figure 3B. Having established the signiﬁcance
of protein expression patterns, protein identities were inves-
tigated using mass spectrometry.
Discriminatory SF Proteome Identiﬁcation, Inter-Sub-
group Variation and Patient Monitoring over Disease Course.
The identities and relative expression levels of the 40 selected
proteins are listed in Table 2. Six albumin isoforms (a, g, h, k,
p and t) were identiﬁed from 11 distinct protein spots,
predominating in cluster 1. Within cluster 3, albumin isoforms
t and k were overexpressed 4.8- (p ) 0.049), 2.9- (p ) 0.018)
and 3.0- (p ) 0.038) fold in extended oligoarticular patients
when compared to the oligoarticular subgroup. Conversely,
albumin isoforms a and g are under expressed 2.7- (p ) 0.021)
and 6.9- (p ) 0.021) fold, respectively, in patients with disease
extension. Intriguingly, albumin complexed with the nonste-
roidal anti-inﬂammatory drug (NSAID) S-naproxen (spot num-
bers 41 and 904) was detected at signiﬁcantly raised levels in
extended oligoarticular contrasted with oligoarticular patients.
Apolipoproteins AI and AII were overexpressed 2.9- (p )
0.008) and 2.6- (p ) 0.046) fold, respectively, in polyarticular
patients when contrasted against oligoarticular and extended
oligoarticular subgroups. In clusters 1 and 3, transferrin was
identiﬁed as two independent protein spots (42,33) represent-
ing nonglycosylated and N-lobe forms. Levels of the nongly-
cosylated transferrin were raised 2.0- (p) 0.014) fold in patients
who showed disease extension, whereas the transferrin N-lobe
displayed the inverse with 2.6- (p ) 0.045) fold less, relative to
oligoarticular patients. Complement component C3c and he-
mopexin display analogous overexpression in polyarticular
patients when balanced alongside oligoarticular and extended
oligoarticular subgroups. Interestingly, from the point of view
of JIA pathology, vitamin D binding protein was detected in
polyarticular patients at signiﬁcantly higher levels, 2.2- (p )
0.019) fold, relative to oligoarticular patients in cluster 1,
Figure 3. Statistical analysis of subgroup comparisons by protein clusters. The signiﬁcance of these clusters to differentiate patient
subgroups was tested by Tukey-Kramer HSD post hoc test of multiple comparisons (A). The unpaired t test revealed proteins with
signiﬁcant intersubgroup variations (B). The p-values are summarized in Table 2 and overlaps of protein expression comparisons
which reached statistical signiﬁcance between subgroups are represented within the Venn diagram.
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whereas the protein was under expressed 2.1- (p ) 0.001) fold
relative to the extended oligoarticular subgroup in cluster 3.
The acute phase reactant, haptoglobin, was positively identi-
ﬁed in extracts from independent spots (900, 24 and 878) and
signiﬁcantly overexpressed in polyarticular patients 2.3- to 4.3-
fold when contrasted with all oligoarticular patients. Two
glycoprotein species of alpha-2-glycoprotein 1 were identiﬁed
in four discrete protein spots (26, 25, 29 and 365), a leucine-
rich and a zinc-complexed species. In addition, several spots
(18, 542 and 699) were identiﬁed as Immunoglubulin (Ig)
fragments within cluster 3 at signiﬁcantly reduced levels in the
patients with disease extension to oligoarticular patients. Ig
heavy chain variable region, IgK1 and Ig light chains were
underexpressed 5.4- (p ) 0.030), 3.0- (p ) 0.023) and 2.9- (p )
0.020) fold in the extended oligoarticular subgroup relative to
the oligoarticular subgroup. A number of protein spots re-
mained unidentiﬁed, attributable to low protein yield from the
gel core extraction process.
Western immunoblotting of synovial ﬂuids and immuno-
histochemistry of synovial membranes from a representative
set of patients validates the mass spectrometry identiﬁcations
of selected proteins, in Figure 4. Western blot apparent band
densities are consistent with levels ascertained from DIGE spot
intensities. Immunohistochemistry reveals perivascular expres-
sion of apolipoprotein II and vitamin D binding protein with
synovial membrane, indicative of macrophage and T-lympho-
cyte activation; complement C3c is not detected.
Synovial ﬂuid samples from patients with recurrent joint
aspirations were used to monitor the panel of proteins as
disease evolves. Data representative of ﬁve patients monitored
in this fashion are shown for a single polyarticuar individual
in Figure 5. Haptoglobin, transferrin, albumin complexed with
S-naproxen and alpha-2-glycoprotein 1 all follow similar trends
within the affected joints over the 2 year period. It was evident
that peaks in levels of these proteins coincided with higher
numbers of inﬂamed joints across the illustrated individual.
In contrast, the nonglycosylated form of transferrin displayed
a gradual decline across the sampled joints, whereas comple-
ment component C3c showed a similar trend up to the 73 week
point before rising to levels detected in the initial sample.
Discussion
This is the ﬁrst study to analyze the synovial proteome in
JIA and relate it to subsequent disease subtypes. Many pro-
Table 2. Mass Spectrometry of Selected Proteinsa
a Protein name, mass spectrometry data, fold differences between subgroups and their statistical signiﬁcance are compiled for the 40 synovial ﬂuid
associated proteins. Spot trypsin digests were identiﬁed using matrix assisted laser desorption ionisation (MALDI-TOF/TOF), correlated to compiled
peptide data (Matrixscience). P-values in bold highlight inter-subgroup comparisons which reached statistical signiﬁcance (p < 0.05) by unpaired t test.
Peptide ion sequence and peak lists can be found in Supplementary Tables 3A-C.
Figure 4. Veriﬁcation of protein expression and localization in
synovial ﬂuid and membrane. Western immunoblotting of syn-
ovial ﬂuids from representative oligoarticular (1-3), extended
oligoarticular (4-6) and polyarticular (7-9) patients (A). Band
densities of vitamin D binding protein, complement C3c and
apolipoprotein II concur with protein expression levels measured
by DIGE. Representative immunohistochemistry of synovial
membrane from a polyarticular patient (B), all captured at 10×
magniﬁcation. Apolipoprotein AII and vitamin D binding protein
expression is perivascular in nature, whereas complement C3c
is not detected.
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inﬂammatory, anti-inﬂammatory and mediators of tissue repair
and destruction have been identiﬁed in JIA.12-15 Conventional
measures of the acute phase response CRP and ESR were
recorded within this study at similar levels in oligo and
extended oligoarticular groups, potentially confounding clinical
differentiation of patients who will likely develop more aggres-
sive disease. Signiﬁcantly higher levels were observed in the
polyarticular patients signifying the increased disease activity
experienced at an early stage by polyarticular patients. Pro-
teomic proﬁles offer us a powerful tool to identify those
biomarker proﬁles present not only in disease subsets, but
which predict evolution into a particular disease subset. Our
results suggest that for each disease subset a proteomic proﬁle
exists and that this proﬁle has the potential to predict disease
evolution. Furthermore, the SF proteomic pattern observed in
an individual patient was consistent between joints of that
patient, possibly reﬂecting the degree of joint inﬂammation.
The consistency of protein pattern across joints suggests that
the biomarker proﬁle truly represents a disease subtype.
Synovial ﬂuid acts as a pool for proteins and peptides
secreted and shed locally from suspended cells, synovial
membrane and cartilage. Potential biomarkers which have
relevance to joint inﬂammatory status and disease progression
can be found at enriched levels within the synovial ﬂuid
proteome.8 The current study has provided evidence that JIA
patient subgroups can be segregated in early disease based on
the clustering patterns of 40 synovial ﬂuid proteins. By exten-
sion of this of this ﬁnding, it is possible to differentiate JIA
patients who suffer disease extension within the ﬁrst year of
diagnosis. Several acute-phase proteins, albumins, glycopro-
teins and immunoglobulins comprise the bulk of the discrimi-
natory subproteome isolated in this study. Though many of
these are abundant in plasma, substantial evidence suggests
these molecules may govern a wide range of inﬂammatory
pathways with bearing on the pathology of JIA, in particular
disease extension.
A number of these proteins belong to the negative acute
phase proteins (APPs) and previous studies suggest that plasma
concentrations decrease in response to inﬂammation because
of increased rates of transcapillary escape degradation.16 It has
been suggested that transient inﬁltration of negative APP
plasma proteins may partially explain the relapse-remission
cycles characteristic of JIA and other forms of inﬂammatory
arthritis.17
Inhibitory acute phase proteins were associated with sig-
niﬁcant differences in JIA subgroup expression patterns. When
compared to the synovial ﬂuid proteome levels of the oligoar-
ticular patient subgroup, apolipoprotein A-I was reduced in
patients with extended oligoarticular disease, whereas apoli-
poprotein A-II was conversely higher. Both apolipoprotein
species were signiﬁcantly raised in the polyarticular patients.
In rheumatoid arthritis patients, apolipoprotein A-I plasma
levels are lower than normal controls,18,19 whereas the levels
are increased in synovial ﬂuid.20,21 Apo A-I immunohistological
staining is conﬁned to perivascular areas within the synovium
of RA patients.22 It has been suggested that Apo A-I could
Figure 5. Intraindividual proteome observation during disease course. A representative MALDI-TOF mass spectra of spot 947 identiﬁed
as vitamin D-binding protein (A). The matched peptide sequences are underlined within the sequence of vitamin D-binding protein.
The expression levels of 6 representative proteins (42, 900, 904, 30, 33, 365) are shown for a series of synovial ﬂuid samples from a
single patient over approximately 2 years (B). The female patient was diagnosed with polyarticular JIA at the age of 3 years old, 3
months after disease onset and was rheumatoid factor negative. The log normalized spot volumes from DIGE images of samples are
plotted against time in weeks. The body above each data point indicates the number of swollen joints at the time of aspiration (encircled
red) and the joint on which DIGE proteome analysis was conducted (black arrow). Samples were taken from the left knee 1 month after
diagnosis (0 weeks) and on subsequent appointments from the left ankle (28 weeks), from the left knee again (73 weeks) and from the
right knee (95 weeks).
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inhibit the production of proinﬂammatory cytokine produc-
tion23 and may limit disease recurrence by inhibition of
interactions between T lymphocytes and monocytes.24
In line with apolipoprotein A-I levels, extended oligoarticular
patients display a general trend toward reduced transferrin,
haptoglobin and complement C3c relative to the other two
patient subgroups. These host-response proteins could be
involved in the spread of inﬂammation to previously unaffected
joints. Haptoglobin has been shown to be involved in angio-
genesis, tissue remodeling and cell migration.25 In addition,
transferrin has also been shown to promote angiogenesis,
whereas decreased levels of complement components may
protect breast cancer cells from complement mediated immune
surveillance.26,27
Complement component C3c is increased in SF in RA
patients versus traumatic arthritis, which correlates to levels
of PMN cells in the SF. Therefore, C3c in SF may elucidate the
inﬂammatory activity in the SM.28 In synovial tissue, distinct
deposits of C3c (and C9) are localized in the synovial vascu-
lature and the synovial lining in adult RA.29 Evidence of
complement activation in synovial ﬂuid is available, but their
role in joint inﬂammation remains unclear.30,31 In addition,
previous studies have identiﬁed vitamin D binding protein as
the costimulatory molecule for a metabolite of C5a resulting
in enhanced chemotactic activity.32
A number of proteins associated with tumor spread were also
identiﬁed in the panel of discriminatory markers. Increased
serum leucine rich alpha-2-glycoprotein (LRG) has been ob-
served in patients with several types of cancer including lung
and liver cancers by 2-DE.33,34 Zinc alpha-2-glycoprotein (ZAG)
is overexpressed in prostate cancer and may be a serum marker
of early tumor development with levels predictive of metastatic
spread.35,36
Conclusions
The samples used in this study were only taken at the time
of initial knee inﬂammation, therefore, are most relevant to
the disease pathology in early disease. The authors consider
this prerequisite vital in the discovery of biomarkers which not
only ‘describe’ the initial disease processes, but may also act
as sentinels to predict subsequent disease outcome. The data
provided indicates that synovial ﬂuid proteome proﬁles could
be used to classify patients based on existing clinical deﬁnitions
and predict disease evolution. By cataloguing the protein
proﬁles of joint status as disease progresses, it may also be
possible to monitor therapeutic response over time. Consider-
ing the heterogeneity of patient outcome in JIA, therapeutic
suppression of synovial joint inﬂammation, while neglecting
the systemic components of chronic disease, may not represent
the best approach to management of nonresponsive disease.
Longer lasting remission could be possible by taking systemic
sentinels into account.
It is envisioned that a simple synovial ﬂuid or plasma sample
will predict the subsequent course of disease for that patient,
thus, enabling early appropriate intervention. This course of
action could avoid months of fruitless treatment, commencing
biologics earlier, and thus reducing pain, disability and joint
damage. As with all translational research, a ﬁnal properly
powered prospective study to assess the robustness of such
biomarkers to predict outcome is required. Cross validation of
putative biomarkers is a vital feature of the study design, in
agreement with published discovery strategies.37
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